Fergus Shanahan

TL;DR: Advances in the drug treatment of inflammatory bowel disease include the development of site-specific delivery systems for 5-aminosalicylate, topically active corticosteroids with minimal systemic bioavailability, and a variety of antagonists to specific inflammatory mediators.

TL;DR: Clinicians should adhere to the principles of evidence-based therapeutics in choosing a probiotic strategy, including: selection from a reputable supplier, with appropriate documentation of contents and shelf life; anticipation of strain-specific effects; avoidance of cocktails without documentation of the activities of each ingredient with absence of interstrain antagonism.

TL;DR: Salmonella infection reduces the small intestinal brush border enzyme activity in mice, with the level of reduction and associated weight loss increasing with dose and duration of infection.

TL;DR: Receptors for FMLP are subepithelial and map to the lamina propria of the gastrointestinal mucosa and are detected in activated peripheral blood phagocytes and epithelial cell lines.

TL;DR: It is indicated that upregulation of FasL expression by colon tumor cells results in an improved anti-tumor immune challenge in vivo, providing functional evidence in favor of the ‘Fas counterattack’ as a mechanism of tumor immune evasion.